Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma

Jianbo Cao, Stephen Pickup, Cynthia Clendenin, Barbara Blouw, Hoon Choi, David Kang, Mark Rosen, Peter J. O'Dwyer, and Rong Zhou

Abstract

Purpose: The dense stroma underlies the drug resistance of pancreatic ductal adenocarcinoma (PDA) and has motivated the development of stroma-directed drugs. Our objective is to test the concept that dynamic contrast-enhanced (DCE) MRI using FDA-approved contrast media, an imaging method sensitive to the tumor microenvironment, can detect early responses to stroma-directed drug.

Experimental Design: Imaging studies were performed in three mouse models exhibiting high desmoplastic reactions: the autochthonous PDA in genetically engineered mice (KPC), an orthotopic model in syngeneic mice, and a xenograft model of human PDA in athymic mice. An investigational drug, PEGPH20 (pegvorhyaluronidase alfa), which degrades hyaluronan (HA) in the stroma of PDA, was injected alone or in combination with gemcitabine.

Results: At 24 hours after a single injection of PEGPH20, Ktrans, a DCE-MRI-derived marker that measures how fast a unit volume of contrast media is transferred from capillaries to interstitial space, increased 56% and 50% from baseline in the orthotopic and xenograft tumors, respectively, compared with a 4% and 6% decrease in vehicle groups (both P < 0.05). Similarly, after three combined treatments, Ktrans in KPC mice increased 54%, whereas it decreased 4% in controls treated with gemcitabine alone (P < 0.05). Consistently, after a single injection of PEGPH20, tumor HA content assessed by IHC was reduced substantially in all three models while drug delivery (measured by paclitaxel accumulation in tumor) was increased by 2.6-fold.

Conclusions: These data demonstrated a DCE-MRI marker, Ktrans, can detect early responses to stroma-directed drug and reveal the sustained effect of combination treatment (PEGPH20 + gemcitabine).

Introduction

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a 5-year survival rate of 6% (1). PDA is characterized by a dense, desmoplastic stroma, populated by proliferating pancreatic stellate cells (PSC), which deposit an extracellular matrix (ECM) including collagen, proteoglycans, and glycosaminoglycans (e.g., hyaluronan or hyaluronic acid [HA]). Accumulation of HA, which is highly water-absorbing, results in a significant increase in interstitial fluid pressure (IFP) in the tumor. This hydrostatic pressure leads to the collapse of blood and lymph vessels, and ultimately hypoperfusion of the tumor (2). The high IFP in combination with a reduced blood vessel density defines a unique tumor microenvironment featuring a profound lack of functional perfusion (3). Contrast-enhanced radiologic imaging often presents a hypoenhanced PDA tumor (4, 5) in contrast to hyperenhanced neuroendocrine pancreatic tumors, which are hypervascular. It has been recognized that this unique tumor microenvironment, where both blood flow and permeability of the microvasculature are reduced, with the consequence that the transport of small-molecule drugs across the capillaries is hindered, underlies the chemoresistance in PDA (3, 6, 7). Besides high IFP, the stroma also harbors an immune-suppressive microenvironment (8). Taken together, the stroma plays an important role in the overall resistance of PDA to treatment; therefore, overcoming this "stromal resistance" has motivated the development of stroma-directed interventions. One barrier to the development and clinical implementation of these drugs is the lack of a robust noninvasive marker that can be used to evaluate the pharmacodynamic effect of the drug, identify responsive patients, and guide combination strategies.

Dynamic contrast-enhanced (DCE)-MRI is sensitive to the tumor microenvironment, especially to changes in microvascular function, that is, permeability and perfusion; hence, it may provide a clinically translatable, quantitative imaging marker to assess responses to stroma-directed therapies. Although its utility to assess antiangiogenic therapies has been examined extensively in the clinic (9), DCE-MRI for stroma-directed therapy was only applied in a couple of pilot studies (10, 11). Therefore, to allow a thorough evaluation of this new application of DCE-MRI, extensive animal model work is necessary, and detailed analyses should provide mechanistic insight of the imaging marker.
hypothesized that a DCE-MRI–derived quantitative marker of microvascular function, $K_{trans}$, can detect the early response of the PDA to stroma-specific treatment. In the experimental design, we employed three PDA models including the autochthonous PDA in genetically engineered mice, an orthotopic model in syngeneic mice, and a xenograft model of human PDA in athymic mice. We used an investigational drug, PEGylated recombinant hyaluronidase PH20 (PEGPH20, generic name as pegvorhyaluronidase), which degrades stromal HA and has shown evidence of efficacy in a randomized, multicenter phase II clinical trial of patients with PDA (HALO-202; ref. 12). We examined the effects of a single PEGPH20 injection and in combination with gemcitabine, an active drug for PDA. We corroborated the imaging results with assessments of tumor HA level and quantitative measurement of drug delivery to the tumor. Our data demonstrated that a quantitative DCE-MRI marker can sensitively detect early responses of PDA to stroma-directed drug and monitor the sustained effect of combination treatment.

**Materials and Methods**

**Materials**

PEGPH20, a polyethylene glycol (PEG)–conjugated recombinant human hyaluronidase enzyme that degrades HA (8), was provided by Halozyme Therapeutics via an institutional material transfer agreement. It was dissolved 3.5 mg/mL in a vehicle (VEH) made of 10 mmol/L histidine and 130 mmol/L sodium chloride (pH 6.5), and an aliquot was diluted in PBS before injection. Human PDA cell line, BxPC-3, was purchased from ATCC, was authenticated using the short tandem repeat DNA profiling, and was used within 50 passages. An FDA-approved contrast agent for clinical MRI, MultiHance (Bracco Diagnostics) was applied to paraffin sections of the tumor as described previously (19), and the stained slides were digitized by high-performance liquid chromatography (HPLC) anion-exchange method.

**PDA mouse models**

All animal procedures were approved by the institutional animal care and use committee (IACUC) of the University of Pennsylvania (Philadelphia, PA). A genetically engineered mouse model harboring a pancreas-specific Cre allele with $p53$ and $Kras$ mutations referred to as the KPC mouse (13), was maintained at the Mouse Hospital of Pancreatic Cancer Research Center of our institution. KPC mice of both sexes were used in this study. A cell line, 4662-KPC, established from a KPC tumor (14), was used to generate the orthotopic model by injection of $1.25 \times 10^6$ cells into the pancreas of syngeneic C57BL/6 mice [9 weeks old, both sexes, Jackson Laboratory (Bar Harbor, Maine)]. A xenograft model was generated in athymic mice [NCR nu/nu, 9 weeks old, both sexes, Charles River Laboratories (Wilmington, MA)] by subcutaneous (subQ) injection of 10 million BxPC-3 cells suspended in 0.1 mL PBS in the hind flank.

**DCE-MRI protocol and pharmacokinetic modeling**

MRI studies were performed using a 9.4T DirectDrive System (Agilent Technologies) interfaced with a 12-cm gradient coil (maximal strength 40 gaus/cm). While under isoflurane anesthesia, the mouse was placed inside a 35-mm ID × 10-cm long quadrature birdcage transceiver coil (M2M). Vital signs including ECG, respiration, and core temperature were monitored (SAI Inc.), and the core temperature was maintained at 37 ± 0.2°C by directing warm air into the bore of the magnet. Both $T_1$ (the longitudinal relaxation time of the tissue before contrast agent injection) mapping and DCE series were applied to multiple axial slices (4–7): one slice containing the left ventricle (LV) of the heart was used to measure the arterial input function (AIF) from the blood signal, whereas remaining slices were used to span the entire tumor.

$T_1$ was mapped for both the blood (in the left ventricle of the heart) and tumor using an ECG-gated inversion recovery technique described previously (15, 16). The DCE series was acquired using an ECG-gated saturation recovery technique to effectively suppress the inflow effect (15, 17). After the acquisition of 10 precontrast images, 0.2 mL of the contrast agent was injected in 10 seconds at a constant rate via a tail vein catheter connected to a syringe pump (Harvard Apparatus) while data acquisition continued until 80 images (for each slice) were obtained. Acquisition parameters include FOV = 32 mm, matrix size = 64 × 64, effective TR = 2 × heart beat = 200 ms, TE = 3 ms, flip angle = 7° (for $T_1$) and 90° for DCE series. During DCE acquisition, the radiofrequency pulse sequence timing was recorded on a microcontroller device, and the record was used to correct ECG-triggering errors during postprocessing. The AIF, DCE series, and $T_1$ maps of the tissue were input to a pharmacokinetic model (15, 18) using the least squares methods. Pixel-wise parametric maps of $K_{trans}$ (the rate constant of transferring unit volume of contrast agent from capillaries to interstitial space, min$^{-1}$), $k_{ep}$ (the rate constant from interstitial space to capillaries, min$^{-1}$), $s_i$ (the intracellular water life time, sec), and $V_e$ (extracellular and extravascular volume fraction, %) were obtained as modeling output.

**Immunostaining**

A recombinant HA-binding probe (HTI-601; Halozyme Therapeutics) was applied to paraffin sections of the tumor as described previously (19), and the stained slides were digitized using an Aperio Scanner (Leica Biosystems). The HA-positive and total pixels were counted in the viable tumor region using the manufacturer’s software (Aperio Positive Pixel Count Algorithm). Four sections per tumor were used to estimate tumor HA content by % positive pixels.

**Quantification of drug (paclitaxel) delivery to the tumor**

At 24 hours after PEGPH20 (or VEH) treatment, paclitaxel formulated in Cremophor-EL and ethanol followed by dilution in saline was intravenously infused (30 mg/kg) over a 30-minute period; 2 hours after infusion, the mouse was euthanized and tumor was harvested. Paclitaxel was extracted from the tumor tissue and quantified by high-performance liquid chromatography.
(HPLC) following a published protocol (20). Briefly, tumor tissue was weighed and homogenized in a 10:1 ratio (v/v) of buffer [10 mmol/L Tris, 1 mmol/L EDTA, and 10% (v/v) glycerol, pH = 7.4] and tissue. The homogenate was extracted with ethyl acetate (1:2 v/v, homogenate/ethyl acetate) and centrifuged for 15 minutes at 16,000 × g. The supernatant was collected, dried under nitrogen, and reconstituted with acetonitrile/water (75:25 v/v). The solution was filtered (0.2 μm) and analyzed on an HPLC (JASCO) equipped with a VIVA C18 column (5 μm 250 × 4.6 mm). The paclitaxel content was estimated using a calibration curve and normalized to the tissue weight.

Data and statistical analysis
Data are presented as mean ± SD. Coefficient of variance (CV = SD/mean) was used to evaluate the repeatability of tumor and blood T10 measurements. Statistical analyses were performed using Prism 6 (GraphPad) or SPSS 22 (IBM). In paired studies, the averaged $K_{trans}$, $k_{ep}$, and $\tau_i$ value of the tumor measured at baseline and posttreatment from the same group of mice were compared using the Wilcoxon signed-rank test. The percent changes relative to baseline were compared between treatment groups using the Mann–Whitney U test. The level of $\alpha$ was set at 0.05 to evaluate significance. The distribution of pixel-wise $K_{trans}$ values of tumors measured at baseline and posttreatment was visualized by histograms that were constructed by calculating frequencies of $K_{trans}$ values in each of the 21 bins: bin #1–20 had a fixed bin width of 0.1 min⁻¹ while bin #21 included all $K_{trans}$ >2 min⁻¹.

Results
Following the treatment and imaging schedule in Fig. 1A–C, we first evaluated whether MRI can detect an early response to stroma-directed drug. MRI was performed at baseline and 24 hours after a single intravenous injection of PEGPH20 (1 mg/kg) or VEH in mice bearing orthotopic tumor (4662-KPC) or human PDA xenograft. For the orthotopic model, mice were studied at 3–4 weeks after tumor inoculation with mean tumor size of 255 mm² (61–630 mm²), whereas for the xenograft model, 6–8 weeks after inoculation with mean tumor size 294 mm² (range: 133–452 mm²). To evaluate DCE-MRI responses to PEGPH20 plus gemcitabine, KPC mice were enrolled at 13–27 weeks after birth with mean tumor size 175 mm² (50–260 mm²). KPC mice received PEGPH20 (or VEH) on day 0, 7, and 14 and gemcitabine (50 mg/kg i.v.) on day 1, 8, and 15. MRI was performed at baseline and again 1–2 days after the treatment was completed.

$K_{trans}$ responds to single or multiple injections of PEGPH20 and to combination treatments
As shown in Fig. 1D, tumor was manually defined on T10 map; pixel-wise dynamic MR signal in the tumor was fit into a pharmacokinetic model with the knowledge of input function (AIF) and T10 to derive parameter maps including $K_{trans}$. The sensitivity of $K_{trans}$ was tested by performing DCE-MRI at 24 hours after a single injection of PEGPH20: the timing coincided with peak depletion of tumor HA reported earlier (21). Paired data revealed a consistent increase of $K_{trans}$ in both orthotopic (Fig. 2A) and human PDA xenograft model (Fig. 2B). In comparison, in most VEH-treated tumors, $K_{trans}$ remained unchanged or decreased. In average, $K_{trans}$ increased 56% from baseline in the orthotopic tumors, and 50% in the xenograft model ($P < 0.05$ for both models, Fig. 2D–E). The rate constant, $k_{ep}$, also exhibited a large increase after PEGPH20 treatment; however, variations in $k_{ep}$ changes were greater than those in $K_{trans}$.

To test responses to repeated injections, three mice were injected with PEGPH20 weekly for 3 weeks. The paired $K_{trans}$ values revealed a substantial increase 24 hours after PEGPH20 injection from the baseline, whereas partial recovery (reduction of $K_{trans}$) was observed between injections (Supplementary Fig. S1). The pattern of $K_{trans}$ change is consistent with the recovery of tumor HA after PEGPH20 treatment (22).

Data and statistical analysis
Data are presented as mean ± SD. Coefficient of variance (CV = SD/mean) was used to evaluate the repeatability of tumor and blood T10 measurements. Statistical analyses were performed using Prism 6 (GraphPad) or SPSS 22 (IBM). In paired studies, the averaged $K_{trans}$, $k_{ep}$, and $\tau_i$ value of the tumor measured at baseline and posttreatment from the same group of mice were compared using the Wilcoxon signed-rank test. The percent changes relative to baseline were compared between treatment groups using the Mann–Whitney U test. The level of $\alpha$ was set at 0.05 to evaluate significance. The distribution of pixel-wise $K_{trans}$ values of tumors measured at baseline and posttreatment was visualized by histograms that were constructed by calculating frequencies of $K_{trans}$ values in each of the 21 bins: bin #1–20 had a fixed bin width of 0.1 min⁻¹ while bin #21 included all $K_{trans}$ >2 min⁻¹.

Changes of $K_{trans}$ distribution in response to PEGPH20 and combined treatment
To gain further insights of how the three models may differ in their intrinsic vascular characteristics and responses to stromal therapy, we analyzed the distribution of $K_{trans}$ values using a histogram approach, where pixel-wise $K_{trans}$ values were pooled from individual tumors in each group. Of the three models at baseline, KPC had the lowest frequency in the lowest bin (0–0.1 min⁻¹) of $K_{trans}$ (Fig. 3A–C). In the xenograft model, KPC distribution was relatively narrower and shifted toward the left compared with the other models. These findings revealed distinct microvascular function (i.e., the xenograft has the lowest perfusion/permeability while the KPC model has the highest), likely determined by their location (subQ vs. orthotopic) and the nature of tumor development (spontaneous vs. implanted).

In response to a single injection of PEGPH20, the orthotopic model showed a remarkable redistribution of $K_{trans}$ (red), which was right-shifted relative to the baseline (black) or to VEH treatment (blue). The bins representing relatively high $K_{trans}$ values (0.5–1.1 min⁻¹) whose frequency increased 50% or more from baseline were marked by # in Fig. 3A, indicating increased perfusion/permeability in response to treatment. In comparison, $K_{trans}$ redistribution from the xenograft model (Fig. 3B) was more limited as there were fewer # marked bins and lower $K_{trans}$ values these bins represent (0.5–0.7 min⁻¹). After three PEGPH20 + gemcitabine treatments, $K_{trans}$ distribution in KPC tumor exhibited a right-shift, featuring a large increase of $K_{trans}$ in bins ranging from 1.0 to 1.5 min⁻¹ and ≥2.1 min⁻¹ (marked by #, Fig. 3C). This data suggest that improvement of microvascular function ($K_{trans}$) was sustained by stromal intervention combined with gemcitabine.

Repeatability of DCE-MRI protocol
To reduce data variability, we standardized the DCE-MRI protocol, including using constant Gd concentration (10 mmol/L), volume, and rate of injection via a syringe pump. Vital
signs were maintained at physiologic level throughout the imaging session. Consequently, a good reproducibility of the protocol was obtained: longitudinal relaxation time ($T_1$) measured from the blood and tumor in all three models revealed low CV of 9% and 10%, respectively, at baseline ($n=23$). However, neither blood nor tumor $T_1$ was sensitive to PEGPH20 or combined treatment (Supplementary Fig. S2A–S2C). Because the clearance of the contrast media takes time, it is not feasible to perform two DCE-MRI sessions in same day to assess the repeatability of $K_{trans}$.

Therefore, we evaluated the VEH-treated mice in paired study separated by 24 hours (Fig. 2A and B). Despite one outlier in Fig. 2A, the mean changes of $K_{trans}$ over 24 hours were quite small (4–6%; Fig. 2D–E), suggesting that the $K_{trans}$ measurement is relatively robust.

IHC and quantitative measurement of drug delivery to corroborate imaging findings

In all three models, immunostaining revealed a remarkable accumulation of HA in tumors of VEH-treated mice and dramatic reduction of HA 24 hours after a single injection of PEGPH20 (Fig. 4A–F). By counting the % of HA-positive pixels in the viable tumor regions, a significant difference in HA content was found between PEGPH20 versus VEH-treated tumors (Fig. 4G). However, the xenograft model has higher HA level than other models.
after treatment—this is consistent with the lower posttreatment $K_{\text{trans}}$ values (mean = 0.318/min) compared with orthotopic (mean = 0.639/min) and KPC (mean = 0.608/min) model (Fig. 2A–C).

To test whether the increase in $K_{\text{trans}}$ (from DCE-MRI) was corroborated by increased drug penetration to the tumor bed, we infused paclitaxel in mice bearing orthotopic PDA at 24 hours after a single injection of PEGPH20 and analyzed tumor tissues by HPLC. Our results demonstrated that PEGPH20 treatment resulted in >2-fold greater paclitaxel accumulation in the tumor (Fig. 5; Supplementary Fig. S3), consistent with improved perfusion/permeability revealed by $K_{\text{trans}}$ results.
Discussion

The unique tumor microenvironment presented by the fibroinflammatory stroma in PDA not only promotes tumor progression but also underlies resistance to treatment. Conflicting results may reflect the complexity of stroma-tumor interactions, because genetic ablation of stromal fibroblasts or the sonic hedgehog (SHH) pathway appeared to enhance tumor aggressiveness (23). Conversely, reversal of desmoplastic stroma by stroma-directed drugs including PEGPH20, vitamin-D analogues (24), SHH inhibitors (25, 26), and CD40 agonist antibody (27) have shown promise to overcome gemcitabine resistance and to extend the survival of KPC mice. Importantly, evidence from clinical trials of PEGPH20 (12) and CD40 (27) suggests that stroma-directed approaches lead to more effective management of PDA. Strikingly, drugs targeting different stromal components or signals induce similar changes in the microvasculature. For example, PEGPH20 selectively degrades HA in the ECM (2, 21), whereas calcitriol/paricalcitol activates the vitamin-D receptors on pancreatic stellate cells (24, 28). Both drugs, however, have been shown to improve microvascular function and penetration of small-molecule drugs into the tumor (21, 24, 28, 29). Considering that microvasculature is an integral part of the stroma, the converging effect of stroma-directed drugs is not surprising, but suggests that an imaging marker sensitive to microvascular function may have general application for various stroma-directed drugs. To date, most DCE-MRI studies have been applied to assess antivascular therapies, which induce a decrease in $K_{trans}$ when the tumor responds positively (9, 30). In contrast, stroma-directed therapy induced an increase in $K_{trans}$, resulting in a more favorable dynamic range and sensitivity of DCE-MRI in this new application, given that PDA is poorly perfused before treatment.

A major effect of PEGPH20 on tumor stroma is to degrade extracellular HA, leading to relief of IFP and reopening of otherwise collapsed microvasculature (2, 21). The improvement of vascular function was captured by DCE-MRI through the $K_{trans}$ metric. Indeed, $K_{trans}$ elevation was detected as early as 24 hours after a single injection of PEGPH20 (Fig. 2), as well as after three combined (PEGPH20 + gemcitabine) treatments (Fig. 2). Increase of $K_{trans}$ was corroborated with reductions of tumor HA level in all three, HA-accumulating PDA models, including autochthonous, orthotopic, and xenograft model. Taken together, the effects of PEGPH20 and treatment-induced DCE-MRI changes were robustly achieved in a variety of stroma-dense tumors. This observation bolsters confidence that the technique may demonstrate applicability in human trials as well. In clinical trials of PEGPH20, the patients’ HA status of the tumor was assessed by endoscopic ultrasound guided biopsy, which cannot sample the entire tumor and is limited in robustness. Validation of DCE-MRI marker would provide a noninvasive, quantitative approach to evaluate the HA level of the entire tumor mass.

$K_{trans}$ represents the combined contribution of vascular permeability and perfusion instead of measuring one or the other. This
feature is inherent with $K_{\text{trans}}$ obtained using FDA-approved small-molecule Gd-contrast agents. For $K_{\text{trans}}$ as a stromal marker, this feature could increase the sensitivity because microvascular permeability and perfusion were both increased after stromal intervention (3). DCE-MRI studies with quantitative endpoints are being evaluated in multicenter clinical trials of other cancers, such as prostate and breast cancer (31–34). Quantitative DCE-MRI in human abdominal applications including PDA will be facilitated by motion-robust, rapid imaging techniques and their feasibility in the clinic has been shown (35–37). A standardized clinical DCE-MRI protocol (38) is expected to help control data variability across centers. In conclusion, the proof-of-the-concept study has shown that DCE-MRI is a sensitive and robust quantitative tool for evaluating stroma-directed inventions in preclinical PDA models, and the data support its further evaluation in clinical trials.

Disclosure of Potential Conflicts of Interest

B. Blouw holds ownership interest (including patents) in Halozyme Therapeutics. D. Kang holds ownership interest (including patents) in Halozyme Therapeutics. P.J. O’Dwyer reports receiving other commercial research support from Pfizer, Genentech, Bristol-Myers Squibb, GlaxoSmithKline, Five Prime, Forty Seven, BBI, Novartis, Celgene, Ineye, Lilly, Array, H3Biomedicine, and Taiho, is a consultant/advisory board member for Genentech, Boehringer Ingelheim, and Celgene; and reports receiving other remuneration as a result of expert testimony for Bayer. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: J. Cao, H. Choi, P.J. O’Dwyer, R. Zhou


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Cao, S. Pickup, C. Clendenin, H. Choi, R. Zhou

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Cao, S. Pickup, B. Blouw, R. Zhou

Figure 4.
Tumor HA level in response to PEGPH20 or VEH treatment. Representative micrographs of immunostaining for HA in tumor sections obtained from VEH or PEGPH20-treated orthotopic (A–B), xenograft (C–D) and KPC (E–F) model. The percentage (mean ± SD) of HA-positive pixels in three models after VEH or PEGPH20 treatment (G). *P < 0.05; **P < 0.005, compared with the respective VEH group. Treatment/HA staining schedules are shown in Fig. 1B.

Figure 5.
PEGPH20 treatment increased chemotherapy drug (paclitaxel) penetration to the tumor. Content of paclitaxel accumulated in the orthotopic tumor after PEGPH20 (n = 3) or VEH treatment (n = 3). *P < 0.05 compared with the respective VEH group. Treatment/euthanasia schedules are shown in Fig. 1B.
Writing, review, and, or revision of the manuscript: J. Cao, H. Choi, D. Kang, M. Rosen, P.J. O’Dwyer, R. Zhou
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Kang, P.J. O’Dwyer, R. Zhou
Study supervision: P.J. O’Dwyer, R. Zhou

Acknowledgments
We thank Dr. Hee Kwon Song for insightful discussions. This study was partially supported by R21CA198563, R01CA211337, and U24CA231858. All MRI studies were performed in the Small Animal Imaging Facility at the University of Pennsylvania which is supported by the Abramson Cancer Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 16, 2018; revised November 20, 2018; accepted December 19, 2018, published first December 26, 2018.

References
32. DCE-MRI Detects PDA Responses to Stroma-directed Drug (P30-CA-106520). J. Cao is grateful for the financial support from the China Scholarship Council (grant no. 201806130135).

www.aacrjournals.org
Clin Cancer Res; 25(7) April 1, 2019
2321


Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma

Jianbo Cao, Stephen Pickup, Cynthia Clendenin, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-18-2276

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2018/12/22/1078-0432.CCR-18-2276.DC1

Cited articles
This article cites 37 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/25/7/2314.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/25/7/2314.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.